Results 31 to 40 of about 1,141 (182)
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin [PDF]
Drugs, 2021 The epidemiology of invasive fungal infections is changing, with new populations at risk and the emergence of resistance caused by the selective pressure from increased usage of antifungal agents in prophylaxis, empiric therapy, and agriculture. Limited antifungal therapeutic options are further challenged by drug-drug interactions, toxicity, and ...
Martin Hoenigl +11 more
openaire +4 more sources
Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model
Pathogens and ImmunityBackground: Endophthalmitis, a severe infection of the intraocular tissues that can result in permanent loss of vision if not immediately treated, is often caused by fungi, namely Candida albicans.
John Saghir +5 more
doaj +2 more sources
Promising antimycotics for the treatment of invasive infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj +1 more source
Activity of rezafungin against Candida auris. [PDF]
J Antimicrob ChemotherAbstract The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality.
Locke JB +8 more
europepmc +3 more sources
Clinical and Translational Science, 2022 Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of
Kenan Gu +6 more
doaj +1 more source
Treatment of Candida glabrata native valve endocarditis with rezafungin: a case report [PDF]
JAC-Antimicrobial ResistanceCastagna A. +4 more
core +4 more sources
Open Forum Infectious Diseases, 2023 Abstract Background Rezafungin (RZF) is a new echinocandin (ECH) approved by the US FDA to treat candidemia and invasive candidiasis (IC). Fluconazole (FLC) resistance (R) is a raising concern to treat IC, and ECHs are often used as first-line therapy.
Carvalhaes, Cecilia G +3 more
openaire +1 more source
Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
Antimicrobial Agents and Chemotherapy, 2021 Rezafungin is a novel antifungal agent of the echinocandin class with potent activity against species ofCandidaandAspergillus, including subsets of resistant strains, andPneumocystis jirovecii. The objective of this analysis was to develop a population pharmacokinetic (PK) model to characterize the disposition of rezafungin in plasma following ...
Christopher M. Rubino, Shawn Flanagan
openaire +2 more sources
Emerging and Future Strategies in the Management of Recalcitrant Candida auris [PDF]
, 2022 Candida auris is an emerging, multi drug resistant fungal pathogen that has caused infectious outbreaks in over 45 countries since its first isolation over a decade ago, leading to in-hospital crude mortality rates as high as 72%.
Bandara, Nihal, Samaranayake, Lakshman
core +3 more sources
Open Forum Infectious Diseases, 2023 Abstract Background Fluconazole (FLC) resistance (R) is common in C. glabrata (CGLA). Echinocandins (ECHs) are often used as first-line therapy. R to ECHs has been associated with FKS1 and FKS2 gene alterations.
Carvalhaes, Cecilia G +4 more
openaire +1 more source